Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Up 327.2% in July

Autonomix Medical, Inc. (NASDAQ:AMIX) was the recipient of a significant increase in short interest in July. As of July 31st, there was short interest totaling 263,441 shares, an increase of 327.2% from the July 15th total of 61,662 shares. Based on an average daily trading volume, of 7,539,029 shares, the days-to-cover ratio is currently 0.0 days. Currently, 28.9% of the shares of the stock are sold short.

Analyst Ratings Changes

AMIX has been the subject of a number of analyst reports. Zacks Research upgraded shares of Autonomix Medical to a “hold” rating in a research report on Tuesday, June 2nd. Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $42.00.

Autonomix Medical Trading Down 5.9%

Shares of AMIX stock traded down $0.41 during trading hours on Friday, hitting $6.45. 87,545 shares of the company’s stock were exchanged, compared to its average volume of 1,553,265. The company has a market capitalization of $6.26 million, a PE ratio of -0.09 and a beta of -1.17. Autonomix Medical has a 12-month low of $2.44 and a 12-month high of $32.55. The business’s 50 day simple moving average is $6.83 and its 200-day simple moving average is $7.74.

Autonomix Medical (NASDAQ:AMIX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.40) by $1.38. Equities analysts anticipate that Autonomix Medical will post -20.17 EPS for the current year.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.